Mutation frequencies of the cytochromeCYP2D6 gene in Parkinson disease patients and in families
- 26 July 1996
- journal article
- Published by Wiley in American Journal of Medical Genetics
- Vol. 67 (4) , 361-365
- https://doi.org/10.1002/(sici)1096-8628(19960726)67:4<361::aid-ajmg8>3.0.co;2-p
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genesAnnals of Neurology, 1994
- Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeHuman Molecular Genetics, 1994
- Mutant debrisoquine hydroxylation genes in Parkinson's diseaseThe Lancet, 1992
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Oxidative polymorphism of debrisoquine in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- DEBRISOQUINE METABOLISM IN PARKINSONIAN PATIENTS TREATED WITH ANTIHISTAMINE DRUGSThe Lancet, 1987
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1985